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INTRODUCTION
Bilirubin is an endogenous antioxidant that protects cells against 
oxidative stress [1]. As heme oxygenase-1 facilitates oxidation to 
generate biliverdin and other substances, it produces anti-inflam-
matory and antioxidative products. Due to the cytoprotective ef-
fect of bilirubin, elevated activity of oxygenase or a rate-limiting 
enzyme in heme, which can be caused by genetic or environmen-
tal factors, has been reported to be beneficial for health overall 
and for injuries [2].
Ischemic heart disease (IHD) remains a major health issue 
worldwide. Previous evidence has shown that inflammation plays 
a key role in the initiation and progression of cardiovascular dis-
ease [3]. In addition, in previous studies, increased plasma levels 
of bilirubin have been associated with a reduced risk of IHD [4,5]. 
Nonetheless, whether those associations reflect a true protective 
effect of bilirubin on IHD, rather than confounding or reverse 
causation, remains unknown [6]. Furthermore, some of those 
studies were conducted in populations at high risk. A recent me-
ta-analysis of 11 studies and a Mendelian randomization (MR)
study reported no relationship between bilirubin levels and IHD 
[7]. To date, the relationship between bilirubin levels and IHD is 
not well-characterized.
Therefore, in the present study, we sought to investigate wheth-
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bilirubin levels (r2 > 0.001). Among them, we removed 1 palin-
dromic SNP (rs2219067) from further analysis. 
Data sources for the study outcome 
IHD was defined as our outcome. The outcome data were ob-
tained from the Korean Cancer Prevention Study-II (KCPS-II) 
cohort, which comprises 156,701 participants (94,840 men and 
61,861 women) who received a medical examination at 18 health 
promotion centers in Seoul and Gyeonggi Province, Korea be-
tween 2004 and 2013. Regular or obligatory health check-ups and 
health issues were most common reasons for their visits. In addi-
tion, participants received regular follow-up. Details about the 
KCPS-II cohort can be found in a previously published cohort 
profile article [9]. Among the participants, subjects with genotype 
and phenotype data who provided written consent were selected 
for further analysis. GWAS analysis was conducted using a logis-
tic regression model with adjustment for age and sex (MAF≥ 0.01, 
p for HWE test≥ 0.0001). Odds for IHD risk were used when cal-
culating ratio estimates. 
Associations of genetic variants with the outcome
A total of 1,910 cases and 11,945 randomly selected controls 
were used to examine the associations of genetic variants with 
IHD. Genotyping was carried out with K-CHIP, using the same 
method as described above. After genotyping, we also performed 
imputation analysis using the 1000G Phase 3 dataset for East Asian 
populations (JPT, CHB) as a reference panel to infer missing gen-
otypes. The quality control procedures for SNPs were conducted 
using the same procedure as for the selection of the study expo-
sure: (1) deviation from HWE (p< 10-4) and (2) MAF< 1%. Lo-
gistic regression adjusted for age and sex was performed to deter-
mine genetic associations with IHD. Statistical analyses were per-
formed using PLINK version 1.07 (http://zzz.bwh.harvard.edu/
plink/). 
Mendelian randomization
Two-sample MR analyses were performed to investigate the ex-
istence of a causal relationship between bilirubin and IHD (Figure 
1). Two-sample MR is an approach used to investigate potential 
causal relationships between modifiable risk factors and an out-
come of interest, using genetic variants as an instrumental varia-
ble (IV). MR studies are more reliable than observational studies, 
and they provide proper guidelines for interventional research 
and public health interventions for population genetics [10]. Un-
like single-sample MR, two-sample MR uses summary associa-
tion results from non-overlapping sets of individuals obtained 
from the published literature or results estimated directly from 
individual-level participant data. The key assumptions of two-
sample MR are (1) the IV is causally related to the risk factor; (2) 
confounding factors of the association between risk factors and 
the outcome should not be related to the IV; and (3) the IV only 
affects the outcome though its effect on risk factors [10,11].
The odds of IHD risk were divided by the β coefficient of bili-
er bilirubin levels are causally related to IHD risk using the two-
sample MR approach in a Korean population.
MATERIALS AND METHODS
Data sources for the study exposure
Genetic associations with bilirubin levels were obtained from 
the Korean Genome and Epidemiology Study (KoGES). The Ko-
GES, which is categorized into population-based and gene-envi-
ronment model studies, is a consortium project consisting of 6 
prospective cohort studies supported by the government funding. 
Over 223,000 participants have been recruited, of whom 35,000 
participants from population-based studies (KoGES_Ansan and 
Ansung Study and KoGES_HEXA Study) and who had epidemi-
ological information and DNA samples were selected. The char-
acteristic details of the KoGES have been previously described [8]. 
In total, 1,402 of the 35,000 participants were excluded through 
the quality control procedure (sex inconsistency: n=127; <97% call 
rate or excessive heterozygosity: n = 635; excessive singletons: 
n= 69; cryptic first-degree relatives: n= 393; and withdrawals and 
blind duplicates: n= 178). Finally, a total of 33,598 participants 
were selected for further analysis (Supplementary Material 1). 
Genomic DNA was extracted from peripheral blood monocytes 
by standard procedures, and single-nucleotide polymorphism 
(SNP) data was obtained using Korean Chip (K-CHIP) as part of 
the K-CHIP consortium. K-CHIP, which contains 830,000 SNPs 
customized for the Korean population, was designed by the Cent-
er for Genome Science of the Korea National Institute of Health 
(http://nih.go.kr/menu.es?mid= a50303010100). To increase the 
coverage of the genome-wide association study (GWAS), we con-
ducted imputation analysis using the 1000 Genomes (1000G) 
Phase 3 dataset of East Asian populations (Japanese in Tokyo 
[JPT], Chinese in Beijing [CHB]) as a reference panel. Haplotype 
phasing with sample genotypes from the 1000G reference panel 
was performed using IMPUTE2 software. For quality control, 
SNPs were excluded prior to the analysis using the following cri-
teria: (1) deviation from Hardy-Weinberg equilibrium (HWE) 
with a p-value less than 10-4 and (2) minor allele frequency (MAF) 
less than 1%. 
Genetic associations of variants with exposure and 
selection of the genetic instrumental variables 
Linear regression with adjustment for age and sex was perform-
ed to examine the associations of genetic variants with bilirubin. 
Statistical analyses were performed using PLINK version 1.07. We 
obtained 1,784 SNPs with a genome-wide significance level (p<10-8). 
For standard two-sample MR, it is crucial to confirm that the in-
struments for the exposure are strongly independent. Thus, we 
examined the clumping test to estimate the linkage disequilibrium 
between selected SNPs using 1000G data (https://mrcieu.github.
io/TwoSampleMR). Finally, a total of 6 independent SNPs 
(rs10490012, rs12993249, rs2119503, rs4149014, rs2219067, and 
rs73233620) were selected as instrumental variables for serum 
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Table 1. Associations of individual genetic instruments for serum bilirubin levels with IHD risk
SNP Nearby gene Chromosome Effect allele
Bilirubin IHD  
β (SE) p-value OR (95% CI) p-value
rs10490012 TRPM8   2 T -0.017 (0.003) 1.15×10-10 1.03 (0.96, 1.11) 0.434
rs12993249 USP40   2 G 0.060 (0.003) 2.36×10-105 1.07 (0.99, 1.15) 0.086
rs2119503 ATG16L1   2 A 0.053 (0.004) 4.63×10-37 1.07 (0.96, 1.19) 0.226
rs4149014 SLCO1B1 12 G -0.024 (0.003) 3.72×10-14 0.99 (0.91, 1.07) 0.744
rs73233620 SLCO1B3 12 G 0.057 (0.003) 1.44×10-65 1.01 (0.92, 1.10) 0.897
IHD, ischemic heart disease; SNP, single-nucleotide polymorphism; SE, standard error; OR, odds ratio; CI, confidence interval.
Table 2. MR for the effects of serum bilirubin on ischemic heart dis-
ease risk
Variables OR (95% CI)  p-value No. of SNPs
Inverse-variance weighted 2.03 (0.87, 4.70) 0.100 5
Weighted median 2.41 (0.89, 6.57) 0.085 5
MR-Egger regression 5
   Estimate 4.94 (0.68, 35.91) 0.213 5
   Intercept, β (SE) -0.04 (0.05) 0.403 5
MR, Mendelian randomization; OR, odds ratio; CI, confidence interval; 
SNP, single-nucleotide polymorphism; SE, standard error. 
Figure 1. Overview of the study design. BMI, body mass index; 
KoGES, Korean Genome and Epidemiology Study; KCPS-II, Korean 
Cancer Prevention Study-II; IHD, ischemic heart disease. 
1 KoGES, Korean Genome and Epidemiology study; 2 KCPS II, Korean Cancer Prevention Study II; 
3) BMI, body mass index
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rubin levels to determine ratio estimates for each IV. The effects of 
the individual genetic instruments were combined using inverse-
variance weighted (IVW) analysis, resulting in a weighted mean 
estimate of the risk for IHD per 1-standard deviation increase in 
serum bilirubin levels. As the IVW method assumes that all ge-
netic variants satisfy the IV assumptions, sensitivity analyses were 
performed with MR–Egger regression and the weighted median 
estimation method. A leave-one-out sensitivity analysis, leaving 
outlying variants out of the MR analysis, was performed, as weak 
instruments were used to predict serum bilirubin levels (Supple-
mentary Material 2). A radial plot was applied to assess heteroge-
neity across genetic variants and to detect pleiotropic variants 
(Supplementary Material 3).
The MR package in R statistical software (MR Base website: 
https://github.com/MRCIEU/TwoSampleMR) was used to per-
form the two-sample MR analysis. 
Ethics statement
The Severance Medical Ethics Committee approved this study 
(no. 4-2011-0277).
RESULTS
Table 1 shows the associations of the 5 SNPs (rs10490012, 
rs12993249, rs2119503, rs4149014, and rs73233620) selected as 
genetic instruments for serum bilirubin levels with IHD risk. For 
the genetic association analysis of bilirubin, 5 SNPs showed suffi-
cient strength to minimize the effects of the weak instrument bias 
in our analysis of bilirubin levels (F-statistics ranged from 37.61 
to 450.09). Among the 5 SNPs, rs12993249 (located near the USP40 
gene on chromosome 2) showed the most significant relationship 
with bilirubin levels (β [standard error, SE]= 0.060 [0.003]; p= 2.36 
× 10-105), followed by rs73233620, which is located on the SLCO1B3 
gene (β [SE]= 0.057 [0.003]; p= 1.44× 10-65) and was previously 
identified in a GWAS analysis of bilirubin. No significant genetic 
associations with IHD risk were found (Table 1).
Table 2 shows the results of the two-sample MR analysis for se-
rum bilirubin levels on IHD risk. Using the 5 genetic variants as 
IVs, we found that bilirubin levels had no significant effect on the 
risk of IHD in East Asians (IVW: OR, 2.03; 95% confidence inter-
val [CI], 0.87 to 4.70; p= 0.100) (Table 2 and Figure 2). The weight-
ed median analyses showed that there was also no significant as-
sociation between bilirubin levels and risk of IHD (OR, 2.41; 95% 
CI, 0.89 to 6.57; p= 0.085) (Table 2 and Figure 2). MR-Egger re-
gression showed non-significant, but much higher risk (OR, 4.94; 
95% CI, 0.68 to 35.91; p= 0.213) compared to the estimates ob-
tained using the IWV and weighted median MR methods. Be-
cause the intercept from the MR-Egger regression analysis showed 
no significant deviation from zero, no evidence for directional 
pleiotropy was observed. A radial plot showed that no significant 
outliers existed among the 5 SNPs (Supplementary Material 3).
DISCUSSION
We conducted a two-sample MR study and found that 5 genetic 
variants were significantly associated with bilirubin levels. Al-
Epidemiol Health 2019;41:e2019034
  |    www.e-epih.org  4
though our results do not provide evidence for a positive effect of 
bilirubin levels on IHD risk, to our knowledge, this is the first 
two-sample MR study to examine the effect of bilirubin levels on 
IHD risk among an East Asian population.
Previous epidemiological studies have shown contradictory re-
sults for associations between bilirubin levels and IHD risk. A re-
cent meta-analysis found an inverse association between total bil-
irubin levels and the risk of cardiovascular disease, which was in-
dependent of established risk factors [4]. However, other studies 
indicated that higher levels of bilirubin showed direct or null as-
sociations with cardiovascular disease risk [12,13]. Our non-caus-
al findings are in line with recent MR studies among European 
populations on IHD that used UGT1A1 and SLCO1B1, which are 
known to be bilirubin metabolism genes, and suggested that bili-
rubin is not causally associated with IHD risk [7] (Supplementary 
Material 4). Similarly, a previous MR study on bilirubin levels in a 
Korean population conducted by our research team demonstrat-
ed a non-causal association between SNPs at the UGT1 locus and 
bilirubin levels [14]. In this context, our study has several 
strengths, including its design and methods. First, we selected 
variants of SLCO1B1/3 as genetic instruments derived from an 
analysis of GWAS data from a Korean population. Because the al-
lele frequencies of SLCO1B1/3 are relatively low or monomorphic 
in European populations, GWAS of bilirubin based on European 
ancestry could not reveal significant novel findings in or nearby 
this gene, in contrast to the findings of Korean GWAS for SL-
CO1B3 variants [15]. Therefore, the genetic instruments used in 
our study may be applicable to East Asian genetic diversity data-
sets. Second, unlike previous MR studies that used summary data 
from large consortia, our study used a single dataset without a 
population substructure, thereby avoiding potential heterogeneity. 
Third, two-sample MR studies are unlikely to have any bias that 
underestimates true causal effects as a result of the weak instru-
ment [16-18]. 
Nonetheless, our study has several potential limitations. First, 
the 5 selected instruments (SNPs) may not be applicable or useful 
in other ethnic groups. Therefore, our study findings may not be 
generalized to other cohorts with different ethnicities. Regarding 
the SLCO1B1/3 (rs4149014, rs73233620) variants, a comparison 
of 1000G Phase 3 data for Caucasian (CEU) and East Asian pop-
ulations revealed notable distinctions in the MAF (CEU: 3.0% for 
rs4149014 and 5.0% for rs73233620; East Asian: 33.3% for rs4149014 
and 17.8% for rs73233620) (Supplementary Material 5). Alterna-
tive instruments may need to be discovered in CEU populations. 
In addition, although MR is suggested to be a fruitful method ca-
pable of overcoming some of the limitations of observational 
studies, the current findings cannot exclude potential inherent bi-
ases and limited causal inferences [19]. 
Nevertheless, identifying additional loci associated with biliru-
bin would yield loci with smaller effect sizes and weights in the 
combined analyses. 
In conclusion, our study provides evidence that bilirubin levels 
may not be causally related to the risk of IHD. While no associa-
tion between serum bilirubin levels and IHD was found, further 
Figure 2. MR analysis regarding the effect of serum bilirubin levels on IHD risk using the genetic instruments. Scatter plot and causal effect 
of serum bilirubin on IHD risk. The X-axis presents the effect of the genetic instrument of serum bilirubin concentration (in mg/dL); the 
Y-axis presents the causal effect of the genetic instrument on IHD risk. MR, Mendelian randomization; IHD, ischemic heart disease; SNP, 
single-nucleotide polymorphism.
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studies that replicate the observed interactions among other eth-
nicities are warranted. 
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Supplementary materials are available at http://www.e-epih.org/.
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